Cognition Therapeutics (CGTX) Short-Term Debt issuances (2022 - 2026)

Cognition Therapeutics (CGTX) has reported Short-Term Debt issuances for 5 consecutive years, with $116000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short-Term Debt issuances fell 3.33% year-over-year to $116000.0 in Q2 2026; TTM through Jun 2026 was $344000.0, a 44.34% decrease from a year earlier, with the FY2025 full-year figure at $353000.0, down 52.23% from the prior year.
• Short-Term Debt issuances was $116000.0 for Q2 2026 at Cognition Therapeutics, up from $113000.0 in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $401000.0 in Q3 2022 and troughed at $41000.0 in Q3 2025.
• A 5-year average of $196000.0 and a median of $183000.0 in 2024 frame the typical range for Short-Term Debt issuances.
• Across the five-year window, Short-Term Debt issuances rose 8.94% in 2024 and tumbled 77.84% in 2025, its largest moves.
• Over 5 years, Short-Term Debt issuances stood at $205000.0 in 2022, then slipped by 12.68% to $179000.0 in 2023, then rose by 8.94% to $195000.0 in 2024, then sank by 62.05% to $74000.0 in 2025, then soared by 56.76% to $116000.0 in 2026.
• The last three Short-Term Debt issuances figures came in at $116000.0 (Q2 2026), $113000.0 (Q1 2026), and $74000.0 (Q4 2025), per Business Quant data.